Intuitive Surgical

Intuitive Surgical (NASDAQ:ISRG) stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 12/22/2023 16.71% Truist Securities $375 → $390 Maintains Buy 12/12/2023 12.23% Truist Securities $320 → $375 Maintains Buy 12/04/2023 -1.24% Morgan Stanley $300 → $330 Maintains Equal-Weight 11/17/2023 4.74% Stifel $315 → $350 Maintains Buy 11/17/2023 -4.83% HSBC → $318 Initiates Coverage On → Buy 10/23/2023 -10.22% Morgan Stanley $330 → $300 Maintains Equal-Weight 10/20/2023 -2.74% Piper Sandler $385 → $325 Maintains Overweight 10/20/2023 6.24% RBC Capital → $355 Reiterates Outperform → Outperform 10/20/2023 16.71% Citigroup $400 → $390 Maintains Buy 10/20/2023 8.63% Wells Fargo $386 → $363 Maintains Overweight 10/20/2023 -7.23% Raymond James $368 → $310 Maintains Outperform 10/16/2023 2.35% Leerink Partners → $342 Initiates Coverage On → Outperform 08/17/2023 7.74% RBC Capital → $360 Reiterates Outperform → Outperform 07/24/2023 -1.24% Morgan Stanley $310 → $330 Maintains Equal-Weight 07/24/2023 15.22% […]

Morgan Stanley analyst Cecilia Furlong maintains Intuitive Surgical (NASDAQ:ISRG) with a Equal-Weight and lowers the price target from $330 to $300.

Intuitive Surgical (ISRG) reported late Thursday Q3 non-GAAP earnings of $1.46 per diluted share, up from $1.19 a year earlier. Analysts polled by Capital IQ expected $1.42. Revenue for the quarter ended Sept. 30 was $1.74 billion, up from $1.56 billion a year earlier. Analysts surveyed by Capital IQ expected $1.77 billion.

Wells Fargo analyst Larry Biegelsen maintains Intuitive Surgical (NASDAQ:ISRG) with a Overweight and lowers the price target from $386 to $363.

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We trim our 12-month target price to $306 from $395, 47.1x our 2024 EPS estimate, in line with ISRG’s historical forward average. We lift our EPS estimate for 2023 by $0.03 to $5.57 and for 2024 by $0.06 to $6.50. ISRG reported Q3 EPS of $1.46 versus $1.19, exceeding the S&P Capital IQ consensus estimate by $0.04. Results were driven by 19% Y/Y growth in da Vinci procedures globally, despite lower patient backlog than earlier in the year, with outside-U.S. procedures growth of 24% due to strength in India, Germany, the U.K., and Japan. Further, the installed base of da Vinci Systems grew 13% Y/Y and average system utilization expanded 6% in the quarter. We forecast full-year 2023 procedure growth of 21.5%, up 50 basis points from

Intuitive Surgical, which makes robotic-surgery systems, says the rollout of weight-loss drugs like Ozempic is pressuring demand for bariatric surgeries in the short term, but the company expects those people to eventually opt for a weight-loss surgery. “In the short-term we will see patients who are considering or are in the pipeline for bariatric surgery going to try the drug,” Chief Medical Officer Myriam Curet tells analysts on a conference call. “However, given compliance issues, cost, side effects, we expect that many of them will not stay on the drugs for longer than a year or two, and at that time will consider bariatric surgery.” Longer term, Curet says the company expects interest in weight loss to grow and boost demand for surgeries. Shares slip 1.6%.

Intuitive Surgical (ISRG) reported late Thursday Q3 non-GAAP earnings of $1.46 per diluted share, up from $1.19 a year earlier. Analysts polled by Capital IQ expected $1.42. Revenue for the quarter ended Sept. 30 was $1.74 billion, up from $1.56 billion a year earlier. Analysts surveyed by Capital IQ expected $1.77 billion.

Intuitive Surgical posted higher third-quarter profit due to a double-digit increase in procedures using its robotic-surgery system. The Sunnyvale, Calif.-based company on Thursday reported a profit of $415.7 million , or $1.16 share, compared with a profit of $324 million, or 90 cents a share, in the same quarter last year. Excluding one-time items, the company reported earnings of $1.46 a share. Analysts recently polled by FactSet expected $1.42 a share. Revenue rose 12% to $1.74 billion, compared with analyst expectations of $1.77 billion. Instruments and accessories revenue rose by 23% to $1.07 billion, helped by a 19% increase in procedures using its da Vinci system and higher prices. The company said its installed base of da Vinci systems stood at 8,285 at the end of the third-quarter, up 13% from a year ago.